Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07 mars 2024 04h00 HE
|
Oxford BioTherapeutics
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...
Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck
18 janv. 2024 04h00 HE
|
Oxford BioTherapeutics
OBT, in collaboration with GORTEC, is evaluating OBT076, an innovative Antibody Drug Conjugate (ADC) targeting CD205 receptor that is highly overexpressed in solid and liquid tumors Oxford, UK,...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung
29 nov. 2023 08h30 HE
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 antigen was discovered using OBT’s proprietary OGAP® drug discovery...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers
24 oct. 2023 09h30 HE
|
Oxford BioTherapeutics
BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets ...
Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies
11 oct. 2023 04h00 HE
|
Oxford BioTherapeutics
Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
03 oct. 2023 02h00 HE
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 proteinDLL3 was discovered using OBT’s proprietary OGAP® drug discovery platformFast...
Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe
05 juil. 2023 04h00 HE
|
Oxford BioTherapeutics
Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe OBT initiates...
Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology
25 mai 2023 04h00 HE
|
Oxford BioTherapeutics
Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck
19 avr. 2023 04h00 HE
|
Oxford BioTherapeutics
Trial will investigate OBT076 as monotherapy and in sequence with balstilimabCD205, OBT076’s target antigen, is overexpressed in ~ 80 % of ACC tumor biopsy samplesRecurrent or metastatic ACC patients...
Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at World ADC Conference 2023
09 mars 2023 04h00 HE
|
Oxford BioTherapeutics
Engine will combine OBT’s internationally recognised target discovery and ADC development capabilitiesOBT will also present a case study and two abstracts focussing on its recent novel target...